Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mineralys Therapeutics, Inc. - Common Stock (NQ: MLYS )

12.95 -0.14 (-1.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mineralys Therapeutics, Inc. - Common Stock

MLYS Stock Earnings: Mineralys Therapeutics Beats EPS for Q4 2023
MLYS stock results show that Mineralys Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Earnings Scheduled For March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. 
Via Benzinga
Mineralys Therapeutics Earnings Preview
Via Benzinga
Where Mineralys Therapeutics Stands With Analysts
Via Benzinga
Where Mineralys Therapeutics Stands With Analysts
Via Benzinga
Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results. 
Via Benzinga
Arm Holdings Posts Upbeat Results, Joins Hershey, CyberArk Software, Wynn Resorts And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mixed, with the Dow Jones gaining around 20 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results. 
Via Benzinga
Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy
From Praxis Bioresearch, Inc.
Via GlobeNewswire
$5M Bet On TreeHouse Foods? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Friday, there were a few notable insider trades. 
Via Benzinga
The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market
The global acute hospital care market was worth $3.2 trillion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.62% from 2023 to 2030. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 74 companies achieved new lows for the year. 
Via Benzinga
Earnings Scheduled For March 15, 2023
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
Via Benzinga
Around $11M Bet On Insight Enterprises? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed lower on Thursday, there were a few notable insider trades. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday, 40 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 42 companies hit new 52-week lows. 
Via Benzinga
There's a Lot to Love About Mineralys' Valentine's Day IPO
MLYS added 20% more shares to IPO funding, which goes live on 2/14. The bump secured liquidity to stabilize development, improving market cap to $683 million 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
Opening Day: Hesai Scores Biggest U.S. Debut By Chinese Company Since Didi
Shares of Hesai, a developer of sensor technologies used in self-driving cars, jumped as much as 29% in its first trading day, making the listing the largest by a Chinese issuer in the U.S. since Didi... 
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.